Beaumont Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Beaumont Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Sell	7,673 -1,803	-19%	-$244K	1.41%	17
2026 Q1	$1.21M	Buy	9,476 +1,935	+26%	+$242K	1.49%	16
2025 Q4	$919K	Buy	+7,541	New	+$865K	1.13%	19
2024 Q4	–	Sell	-2,329	Closed	-$230K	–	55
2024 Q3	$230K	Buy	+2,329	New	+$229K	0.17%	45

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Beaumont Capital Management's XBI Position: Q2 2026 in Review

Beaumont Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 19% in Q2 2026, selling an estimated $244K and leaving 7,673 shares worth $1.21M. The position accounts for 1.41% of the portfolio, ranked #17.

Beaumont Capital Management first reported a position in XBI in Q3 2024 and has held it in 4 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Beaumont Capital Management held 7,673 shares of State Street SPDR S&P Biotech ETF worth $1.21M as of Q2 2026.
Beaumont Capital Management sold 1,803 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $244K.
State Street SPDR S&P Biotech ETF made up 1.41% of Beaumont Capital Management's portfolio in Q2 2026, its #17 holding.
Beaumont Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 4 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Beaumont Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.